Download PDF
Endoscopy
DOI: 10.1055/a-2387-9170
Innovations and brief communications

Use of peroral cholangiopancreatoscopy-assisted endoscopic mucosal resection for biliopancreatic intraductal lesions

Wengang Zhang
1   Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Yaqi Zhai 
1   Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Bozong Shao
1   Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Jiafeng Wang
1   Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Qingzhen Wu
1   Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Ningli Chai
1   Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Enqiang Linghu 
1   Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
› Author AffiliationsSupported by: Chinese PLA General Hospital Young Independent Innovation Science Fund 22QNFC072

Clinical Trial: Registration number (trial ID): ChiCTR2200063675, Trial registry: Chinese Clinical Trial Registry (http://www.chictr.org/), Type of Study: Prospective study
› Further Information
Also available at
  PDF Download

Background and study aim: This study aimed to assess the feasibility and safety of performing cholangiopancreatoscopy-assisted endoscopic mucosal resection (CA-EMR) for biliopancreatic intraductal lesions. Patients and methods: Special electrocautery snares and injection needles that can pass through the working channel of a single-operator cholangiopancreatoscope (SOC) were developed. Between November 2023 and April 2024, we performed CA-EMR for 2 patients with gallbladder polyps, 1 patient a neoplastic lesion in the common bile duct (CBD) and 1 patient with a neoplastic lesion in the main pancreatic duct (PD). The technical success rate and adverse events were recorded. Results: All 4 CA-EMR procedures were performed successfully. Postoperative pathology revealed inflammatory gallbladder polyps in 2 patients, low grade intraepithelial neoplasia (LGIN) of CBD in 1 patient and intraductal papillary mucinous neoplasm (IPMN) in 1 patient. The patient with IPMN experienced mild postoperative pancreatitis and recovered after conservative treatment. No adverse events were encountered in the other 3 CA-EMR procedures. Conclusion: This study preliminarily confirmed the feasibility and safety of CA-EMR for treating biliopancreatic intraductal lesions.



Publication History

Received: 01 May 2024

Accepted after revision: 14 August 2024

Accepted Manuscript online:
14 August 2024

© . Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany